CurveBeam AI

FDA Clearance And AI Advances Will Unlock Future Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 Apr 25

Updated

05 Sep 25

AnalystConsensusTarget's Fair Value

AU$0.15

40.0% undervalued

05 Sep

AU$0.09

-33.3%

-10.0%

-33.3%

-10.0%

You can edit this narrative until Sep 6 10:20 AM. Then, changes will post as Updates.

Author's Valuation

AU$0.1540.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on05 Sep 25

As key valuation metrics such as the Future P/E and Discount Rate for CurveBeam AI showed only marginal shifts, the analyst consensus price target was maintained at A$0.15. What's in the News Auditor PricewaterhouseCoopers LLP expressed substantial doubt about CurveBeam AI's ability to continue as a going concern in the latest annual filing.

Shared on01 May 25
Fair value Increased 15%

Shared on24 Apr 25
Fair value Decreased 28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

AU$0.15

40.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

43.86%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.50%

Calculation

AU$6.60m

Earnings '28

11.23x

PE Ratio '28

AU$74.14m

Market Cap '28

AU$74.14m

Market Cap '28

389.34m

No. shares '28

AU$0.19

Share Price '28

AU$0.19 Share Price '28

Discounted to 2025 @ 8.31% p.a.

AU$0.15

Fair Value '25

FDA Clearance And AI Advances Will Unlock Future Markets

Shared on05 Sep 25

Shared on01 May 25Fair value Increased 15%

Shared on24 Apr 25Fair value Decreased 28%

Shared on17 Apr 25

Shared on01 May 25
Fair value Increased 15%

Shared on24 Apr 25
Fair value Decreased 28%